<DOC>
	<DOC>NCT02571998</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory acne vulgaris.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Nonpregnant female subjects ≥ 12 years of age with facial acne vulgaris Subjects with an Investigator's Global Assessment (IGA) of Inflammatory Lesions of Acne Vulgaris of Moderate (3) or Severe (4) at Baseline. Subjects with ≥ 30 facial inflammatory lesions Subjects with &lt; 10 or &gt; 75 facial noninflammatory lesions Subjects with &gt; 3 facial nodular or cystic lesions at Baseline Standard exclusion criteria</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>